Hyponatraemia: More than just a marker of disease severity?

Nature Reviews Nephrology

Volumn 9, Issue 1, 2013, Pages 37-50

  Schrier, Robert W ^a   Sharma, Shailendra ^a   Shchekochikhin, Dmitry ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CYCLOPHOSPHAMIDE; DIURETIC AGENT; VINBLASTINE; VINCRISTINE;

ADRENAL INSUFFICIENCY; CANCER PATIENT; CHRONIC KIDNEY DISEASE; DISEASE MARKER; DISEASE SEVERITY; EXERCISE; FALL RISK; FALLING; FRACTURE; GERIATRIC PATIENT; HEART FAILURE; HUMAN; HYPONATREMIA; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER CIRRHOSIS; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 84871614954     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.246     Document Type: Review

References (176)

1. Schrier, R. W. Body water homeostasis: clinical disorders of urinary dilution and concentration. J. Am. Soc. Nephrol. 17, 1820-1832 (2006).
2. Hawkins, R. C. Age and gender as risk factors for hyponatremia and hypernatremia. Clin. Chim. Acta 337, 169-172 (2003).
3. Owen, J. A. & Campbell, D. G. A comparison of plasma electrolyte and urea values in healthy persons and in hospital patients. Clin. Chim. Acta 22, 611-618 (1968).
4. Hoorn, E., Lindemans, J. & Zietse, R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol. Dial. Transplant. 21, 70-76 (2006).
5. DeVita, M. V., Gardenswartz, M. H., Konecky, A. & Zabetakis, P. Incidence and etiology of hyponatremia in an intensive care unit. Clin. Nephrol. 34, 163-166 (1990).
6. Ayus, J. C., Achinger, S. G. & Arieff, A. Brain cell volume regulation in hyponatremia: role of sex, age, vasopressin, and hypoxia. Am. J. Physiol. Renal Physiol. 295, F619-F624 (2008).
7. Bradley, E. L., Etheridge, M. S. & Arieff, A. I. Causes of brain damage in patients with severe symptomatic hyponatremia: analysis of 344 patients over 30 years [abstract]. J. Am. Soc. Nephrol. 16, 44A (2005).
8. Waikar, S. S., Mount, D. B. & Curhan, G. C. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am. J. Med. 122, 857-865 (2009).
9. Doshi, S. M., Shah, P., Lei, X., Lahoti, A. & Salahudeen, A. K. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am. J. Kidney Dis. 59, 222-228 (2012).
10. Wald, R., Jaber, B. L., Price, L. L., Upadhyay, A. & Madias, N. E. Impact of hospital-associated hyponatremia on selected outcomes. Arch. Intern. Med. 170, 294-302 (2010).
11. Chawla, A., Sterns, R. H., Nigwekar, S. U. & Cappuccio, J. D. Mortality and serum sodium: do patients die from or with hyponatremia? Clin. J. Am. Soc. Nephrol. 6, 960-965 (2011).
12. Zilberberg, M. D. et al. Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study. BMC Pulm. Med. 8, 16 (2008).
13. Klein, L. et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure. Circulation 111, 2454-2460 (2005).
14. Biggins, S. W. et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 41, 32-29 (2005).
15. Pokaharel, M. & Block, C. A. Dysnatremia in the ICU. Curr. Opin. Crit. Care 17, 581-593 (2011).
16. Stelfox, H. T. et al. The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units. Can. J. Anaesth. 57, 650-658 (2010).
17. DeVita, M. V., Gardenswartz, M. H., Konecky, A. & Zabetakis, P. M. Incidence and etiology of hyponatremia in an intensive care unit. Clin. Nephrol. 34, 163-166 (1990).
18. Funk, G. C. et al. Incidence and prognosis of dysnatremias present on ICU admission. Intensive Care Med. 36, 304-311 (2010).
19. Caird, F. I., Andrews, G. R. & Kennedy, R. D. Effect of posture on blood pressure in the elderly. Br. Heart J. 35, 527-530 (1973).
20. Miller, M., Hecker, M. S. & Friedlander, D. A. Apparent idiopathic hyponatremia in an ambulatory geriatric population. J. Am. Geriatr. Soc. 44, 404-408 (1996).
21. Anpalahan, M. Chronic idiopathic hyponatremia in older people due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) possibly related to aging. Q. J. Med. 101, 583-588 (2008).
22. Miller, M. Hyponatremia: age-related risk factors and therapy decisions. Geriatrics 53, 32-48 (1998).
23. Kleinfeld, M., Casimir, M. & Borra, S. Hyponatremia as observed in a chronic disease facility. J. Am. Geriatr. Soc. 27, 156-161 (1979).
24. Sunderam, S. G. & Mankikar, G. D. Hyponatremia in the elderly. Age Ageing 12, 77-80 (1983).
25. Miller, M., Morley, J. F. & Rubinstein, L. Z. Hyponatremia in a nursing home population. J. Am. Geriatr. Soc. 43, 1410-1413 (1995).
26. Bettari, L. et al. Hyponatremia and long-term outcomes in chronic heart failure-an observational study from the Duke Databank for Cardiovascular Diseases. J. Card. Fail. 18, 74-81 (2012).
27. Konstam, M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319-1331 (2007).
28. Shorr, A. F. et al. Burden of sodium abnormalities in patients hospitalized for heart failure. Congest. Heart Fail. 17, 1-7 (2011).
29. DeWolfe, A., Lopez, B., Arcement, L. M. & Hebert, K. Low serum sodium as a poor prognostic indicator for mortality in congestive heart failure patients. Clin. Cardiol. 33, E13-E17 (2010).
30. Mohammed, A. A. et al. Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study. Circ. Heart Fail. 3, 354-361 (2010).
31. Klein, L. et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111, 2454-2460 (2005).
32. Gheorghiade, M. et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch. Intern. Med. 167, 1998-2005 (2007).
33. Solà, E. et al. Factors related to quality of life in patients with cirrhosis and ascites. Relevance of serum sodium concentration and leg edema. J. Hepatol. http://dx.doi.org/10.1016/j.jhep.2012.07.020.
34. Shaikh, S., Mal, G., Khalid, S., Baloch, G. H. & Akbar, Y. Frequency of hyponatraemia and its influence on liver cirrhosis-related complications. J. Pak. Med. Assoc. 60, 116-120 (2010).
35. Kim, J. H. et al. The association between the serum sodium level and the severity of complications in liver cirrhosis. Korean J. Intern. Med. 24, 106-112 (2009).
36. Yun, B. C. et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 49, 1610-1615 (2009).
37. Angeli, P., Wong, F., Watson, H. & Ginès, P. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 44, 1535-1542 (2006).
38. Berghmans, T., Paesmans, M. & Body, J. J. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer 8, 192-197 (2000).
39. Doshi, S. M., Shah, P., Lei, X., Lahoti, A. & Salahudeen, A. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am. J. Kidney Dis. 59, 222-228 (2012).
40. Nair, V., Niederman, M. S., Masani, N. & Fishbane, S. Hyponatremia in community-acquired pneumonia. Am. J. Nephrol. 27, 184-190 (2007).
41. Kovesdy, C. P. et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation 125, 677-684 (2012).
42. Waikar, S. S., Curhan, G. C. & Brunelli, S. M. Mortality associated with low serum sodium concentration in maintenance hemodialysis. Am. J. Med. 124, 77-84 (2011).
43. Almond, C. S. et al. Hyponatremia among runners in the Boston Marathon. N. Engl. J. Med. 352, 1550-1556 (2005).
44. Knechtle, B., Knechtle, P. & Rosemann, T. Low prevalence of exercise-associated hyponatremia in male 100 km ultra-marathon runners in Switzerland. Eur. J. Appl. Physiol. 111, 1007-1016 (2011).
45. Kipps, C., Sharma, S. & Pedoe, D. T. The incidence of exercise-associated hyponatraemia in the London marathon. Br. J. Sports Med. 45, 14-19 (2011).
46. Mettler, S. et al. Hyponatremia among runners in the Zurich Marathon. Clin. J. Sport Med. 18, 344-349 (2008).
47. Gankam Kengne, F., Andres, C., Sattar, L., Melot, C. & Decaux G. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 101, 583-588 (2008).
48. Sandhu, H. S., Gilles, E., DeVita, M. V., Panagopoulos, G. & Michelis, M. F. Hyponatremia associated with large-bone fracture in elderly patients. Int. Urol. Nephrol. 41, 733-737 (2009).
49. Beck, L. H. Changes in renal function with aging. Clin. Geriatr. Med. 14, 199-209 (1998).
50. Chen, L. K., Lin, M. H., Hwang, A. J. & Chen, T. W. Hyponatremia among the institutionalized elderly in 2 long-term care facilities in Taipei. J. Chin. Med. Assoc. 69, 115-119 (2006).
51. Schrier, R. W., Berl, T. & Anderson, R. J. Osmotic and non-osmotic control of vasopressin release. Am. J. Physiol. 236, F321-F322 (1979).
52. Rudman, D. et al. Hyponatremia in tube-fed elderly men. J. Chronic Dis. 39, 73-80 (1986).
53. Goldstein, C. S., Braunstein, S. & Goldfarb, S. Idiopathic syndrome of inappropriate antidiuretic hormone secretion possibly related to advanced age. Ann. Intern. Med. 99, 185-188 (1983).
54. Renneborg, B., Musch, W., Vandemergel, X., Manto, M. & Decaux, G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am. J. Med. 119, 71.e1-71.e8 (2006).
55. Gosch, M., Joosten-Gstrein, B., Heppner, H. J. & Lechleitner, M. Hyponatremia in geriatric inhospital patients: effects on results of a comprehensive geriatric assessment. Gerontology 58, 430-440 (2012).
56. Thaler, S. M., Teitelbaum, I. & Berl, T. "Beer potomania" in non-beer drinkers: effect of low dietary solute intake. Am. J. Kidney Dis. 31, 1028-1031 (1998).
57. Kugler, J. P. & Hustead, T. Hyponatremia and hypernatremia in the elderly. Am. Fam. Physician 61, 3623-3630 (2000).
58. Clayton, J. A., Rodgers, S., Blakey, J., Avery, A. & Hall, I. P. Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br. J. Clin. Pharmacol. 61, 87-95 (2006).
59. Berl, T. & Schrier, R. Disorders of water metabolism. In Renal and Electrolyte Disorders 6th edn (ed. Schrier, R.) (Philadelphia, Lippincott Williams & Wilkins, 2003).
60. Jencks, S. F., Williams, M. V. & Coleman, E. A. Rehospitalizations among patients in the Medicare fee-for-service program. N. Engl. J. Med. 360, 1418-1429 (2009).
61. Allen, L. A. et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ. Cardiovasc. Qual. Outcomes 4, 389-398 (2011).
62. Gottlieb, S. S. et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J. Card. Fail. 8, 136-141 (2002).
63. Schrier, R. W. Blood urea nitrogen (BUN) and serum creatinine: not married in heart failure. Circ. Heart Fail. 1, 2-5 (2008).
64. Lilly, L., Dzau, V., Williams, G., Rydstedt, L. & Hollenberg, N. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J. Clin. Endocrinol. Metab. 52, 924 (1984).
65. Szatalowicz, V. L. et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N. Engl. J. Med. 305, 263-266 (1981).
66. Riegger, G. A., Leibau, G. & Kochsiek, K. Antidiuretic hormone in congestive heart failure. Am. J. Med. 72, 49 (1982).
67. Goldsmith, S. R., Francis, G. S., Cowley, A. W., Levine, T. B. & Cohn, J. N. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. 1, 1385 (1983).
68. Kim, J. K. et al. Arginine vasopressin gene expression in chronic cardiac failure in rats. Kidney Int. 38, 818-822 (1990).
69. Abraham, W. T. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 341, 577-585 (1999).
70. Schrier, R. W. Body fluid regulation in health and disease: a unifying hypothesis. Ann. Intern. Med. 113, 155-159 (1990).
71. Riegger, G. A., Liebau, G., Bauer, E. & Kochsiek, K. Vasopressin and renin in high output heart failure of rats: hemodynamic effects of elevated plasma hormone levels. J. Cardiovasc. Pharmacol. 7, 1-5 (1985).
72. Forfia, P. R. et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 177, 1364-1369 (2008).
73. Scherz, N. et al. Prognostic importance of hyponatremia in patients with acute pulmonary embolism. Am. J. Respir. Crit. Care Med. 182, 1178-1183 (2010).
74. Crestanello, J. A. et al. Preoperative hyponatremia predicts outcomes after cardiac surgery. J. Surg. Res. http://dx.doi.org/10.1016/j.jss.2012.06. 004.
75. Abraham, W., Shamshirsaz, A., McFann, K., Oren, R. & Schrier, R. W. Aquaretic effect of lixivaptan, an oral non-peptide selective V2 receptor vasopressin antagonist, in the New York Heart Association Functional class II and III chronic failure patients. J. Am. Coll. Cardiol. 47, 1615-1621 (2006).
76. Kindermann, I. et al. Cognitive function in patients with decompensated heart failure: the Cognitive Impairment in Heart Failure (CogImpair-HF) study. Eur. J. Heart Fail. 14, 404-413 (2012).
77. Gheorghiade, M. et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297, 1332-1343 (2007).
78. Ginés, P. & Schrier, R. W. Renal failure in cirrhosis. N. Engl. J. Med. 361, 1279-1290 (2009).
79. Ginés, P. et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 28, 851-864 (1998).
80. Martin, P. Y., Gines, P. & Schrier, R. W. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N. Engl. J. Med. 339, 533-541 (1998).
81. Bichet, D., Szatalowicz, V., Chaimovitz, C. & Schrier, R. W. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann. Intern. Med. 96, 413-417 (1982).
82. Porcel, A. et al. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch. Intern. Med. 162, 323-328 (2002).
83. Gines, A. et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105, 229-236 (1993).
84. Guevara, M. et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int. 30, 1137-1142 (2010).
85. Schrier, R. W. et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355, 2099-2112 (2006).
86. Gines, P. et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48, 204-213 (2008).
87. Cárdenas, A. et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J. Hepatol. 56, 571-578 (2011).
88. Hackworth, W. A. et al. Effect of hyponatraemia on outcomes following orthotopic liver transplantation. Liver Int. 29, 1071-1077 (2009).
89. Dawwas, M. F. et al. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl. 13, 1115-1124 (2007).
90. Yun, B. C. et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 49, 1610-1615 (2009).
91. DiScala, V. A. & Kinney, M. J. Effects of myxedema on the renal diluting and concentrating mechanism. Am. J. Med. 50, 325-335 (1971).
92. Chen, Y. C. et al. Nonosmotic release of vasopressin and renal aquaporins in impaired urinary dilution in hypothyroidism. Am. J. Physiol. Renal Physiol. 289, F672-F678 (2005).
93. Warner, M. H., Holding, S. & Kilpatrick, E. S. The effect of newly diagnosed hypothyroidism on serum sodium concentrations: a retrospective study. Clin. Endocrinol. (Oxf.) 64, 598-599 (2006).
94. Oelkers, W. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N. Engl. J. Med. 321, 492-496 (1989).
95. Diringer, M. N. & Zazulia, A. R. Hyponatremia in neurologic patients: consequences and approaches to treatment. Neurologist 12, 117-126 (2006).
96. Dhar, R. & Murphy-Human, T. A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury. Neurocrit. Care 14, 97-102 (2011).
97. Dubovsky, S. L., Grabon, S., Berl, T. & Schrier, R. W. Syndrome of inappropriate secretion of antidiuretic hormone with exacerbated psychosis. Ann. Intern. Med. 79, 551-554 (1973).
98. Hill, A. R., Uribarri, J., Mann, J. & Berl, T. Altered water metabolism in tuberculosis: role of vasopressin. Am. J. Med. 88, 357-364 (1990).
99. Breuer, R. & Rubinow, A. Inappropriate secretion of antidiuretic hormone and mycoplasma pneumonia infection. Respiration 42, 217-219 (1981).
100. Farber, M. O. et al. Abnormalities of sodium and H2O handling in chronic obstructive lung disease. Arch. Intern. Med. 142, 1326-1330 (1982).
101. Kaskavage, J. & Sklansky, D. Hyponatremia-associated rhabdomyolysis following exercise in an adolescent with cystic fibrosis. Pediatrics 130, e220-e223 (2012).
102. Baratz, R. A. & Ingraham, R. C. Renal hemodynamics and antidiuretic hormonerelease associated with volume regulation. Am. J. Physiol. 198, 565-570 (1960).
103. Letmaier, M. et al. Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int. J. Neuropsychopharmacol. 15, 739-748 (2012).
104. Wilkinson, T. J., Begg, E. J., Winter, A. C. & Sainsbury, R. Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. Br. J. Clin. Pharmacol. 47, 211-217 (1999).
105. Moyses, Z. P., Nakandakari, F. K. & Magaldi, A. J. Fluoxetine effect on kidney water reabsorption. Nephrol. Dial. Transplant. 23, 1173-1178 (2008).
106. Burgess, C., O'Donohoe, A. & Gill, M. Agony and ecstasy: a review of MDMA effects and toxicity. Eur. Psychiatry 15, 287-294 (2000).
107. Tang, W. W., Kaptein, E. M., Feinstein, E. I. & Massry, S. G. Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Am. J. Med. 94, 169-174 (1993).
108. Verbalis, J. G. et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur. J. Endocrinol. 164, 725-732 (2011).
109. Rosenthal, S. M. et al. Nephrogenic syndrome of inappropriate antidiuresis. N. Engl. J. Med. 352, 1884-1890 (2005).
110. Chung, H. M., Kluge, R., Schrier, R. W. & Anderson, R. J. Clinical assessment of extracellular fluid volume in hyponatremia. Am. J. Med. 83, 905-908 (1987).
111. Decaux, G. & Musch, W. Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin. J. Am. Soc. Nephrol. 3, 1175-1184 (2008).
112. Fenske, W. et al. Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics. J. Clin. Endocrinol. Metab. 93, 2991-2997 (2008).
113. Fenske, W. et al. Copeptin in the differential diagnosis of hyponatremia. J. Clin. Endocrinol. Metab. 94, 123-129 (2009).
114. Ellison, D. H. & Berl, T. Clinical practice. The syndrome of inappropriate antidiuresis. N. Engl. J. Med. 356, 2064-2072 (2007).
115. Fenske, W., Maier, S. K., Blechschmidt, A., Allolio, B. & Störk, S. Utility and limitations of the traditional diagnostic approach to hyponatremia: a diagnostic study. Am. J. Med. 123, 652-657 (2010).
116. Young, M., Sciurba, F. & Rinaldo, J. Delirium and pulmonary edema after completing a marathon. Am. Rev. Respir. Dis. 136, 737-739 (1987).
117. Noakes, T. D., Goodwin, N., Rayner, B. L., Branken, T. & Taylor, R. K. Water intoxication: a possible complication during endurance exercise. Med. Sci. Sports Exerc. 17, 370-375 (1985).
118. Speedy, D. B. et al. Hyponatremia in ultradistance triathletes. Med. Sci. Sports Exerc. 31, 809-815 (1999).
119. Petzold, A., Keir, G. & Appleby, I. Marathon related death due to brainstem herniation in rehydration-related hyponatraemia: a case report. J. Med. Case Rep. 1, 186 (2007).
120. Siegel, A. J. et al. Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am. J. Med. 120, 461.e11-461.e17 (2007).
121. Hew-Butler, T. et al. Changes in copeptin and bioactive vasopressin in runners with and without hyponatremia. Clin. J. Sport Med. 21, 211-217 (2011).
122. Ayus, J. C., Varon, J. & Arieff, A. I. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann. Intern. Med. 132, 711-714 (2000).
123. Wakui, A. Electrolyte abnormalities associated with cancer: a review [Japanese]. Gan. To. Kagaku Ryoho 13, 2031-2038 (1986).
124. Gill, G. et al. Characteristics and mortality of severe hyponatraemia - a hospital-based study. Clin. Endocrinol. (Oxf.) 65, 246-249 (2006).
125. Berghmans, T. Hyponatremia related to medical anticancer treatment. Support Care Cancer 4, 341-350 (1996).
126. Bennett, H. E., Bishop, M., Zadik, T. D. & Lincoln, N. B. Cognitive impairment after transurethral resection of the prostate (TURP). Disabil. Rehabil. 26, 1381-1387 (2004).
127. Sorensen, J. B., Andersen, M. K. & Hansen, H. H. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J. Intern. Med. 238, 97-110 (1995).
128. Schwartz, W. B., Bennett, W., Curelop, S. & Bartter, F. C. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am. J. Med. 23, 529-542 (1957).
129. Morton, J. J., Kelly, P. & Padfield, P. L. Antidiuretic hormone in bronchogenic carcinoma. Clin. Endocrinol. (Oxf.) 9, 357-370 (1978).
130. Shapiro, J. & Richardson, G. E. Hyponatremia of malignancy. Crit. Rev. Oncol. Hematol. 18, 129-135 (1995).
131. List, A. F. et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J. Clin. Oncol. 4, 1191-1198 (1986).
132. Odell, W. D. & Wolfsen, A. R. Humoral syndromes associated with cancer. Annu. Rev. Med. 29, 379-406 (1978).
133. Ferlito, A., Rinaldo, A. & Devaney, K. O. Syndrome of inappropriate antidiuretic hormone secretion associated with head neck cancers: review of the literature. Ann. Otol. Rhinol. Laryngol. 106, 878-883 (1997).
134. Onitilo, A. A., Kio, E. & Doi, S. A. R. Tumor-Related Hyponatremia. Clin. Med. Res. 5, 228-237 (2007).
135. Hamdi, T. et al. Cisplatin-induced renal salt wasting syndrome. South Med. J. 103, 793-799 (2010).
136. Iihoshi, M., Sakuragi, T., Higa, K. & Hamada, T. Severe hyponatremia during transurethral resection of prostate [Japanese]. Masui 54, 414-417 (2005).
137. Issa, M. M., Young, M. R., Bullock, A. R., Bouet, R. & Petros, J. A. Dilutional hyponatremia of TURP syndrome: a historical event in the 21st century. Urology 64, 298-301 (2004).
138. Hwang, C. B. et al. Absorption of irrigating fluid during transcervical resection of endometrium - a report of two cases. Acta Anaesthesiol. Sin. 35, 45-50 (1997).
139. Ayus, J. C., Wheeler, J. M. & Arieff, A. I. Postoperative Hyponatremic Encephalopathy in Menstruant Women. Ann. Intern. Med. 117, 891-897 (1992).
140. Choong, K. et al. Hypotonic versus isotonic maintenance fluids after surgery for children: a randomized controlled trial. Pediatrics 128, 857-866 (2011).
141. Yung, M. & Keeley, S. Randomised controlled trial of intravenous maintenance fluids. J. Paediatr. Child. Health. 45, 9-14 (2009).
142. Moritz, M. L. & Ayus, J. C. Prevention of hospital-acquired hyponatremia: a case for using isotonic saline. Pediatrics 111, 227-230 (2003).
143. Bergstrom, W. H. The participation of bone in total body sodium metabolism in the rat. J. Clin. Invest. 34, 997-1004 (1955).
144. Bergstrom, W. H. & Wallace, W. M. Bone as a sodium and potassium reservoir. J. Clin. Invest. 33, 867-873 (1954).
145. Verbalis, J. G. et al. Hyponatremia-induced osteoporosis. J. Bone Miner. Res. 25, 554-563 (2010).
146. Barsony, J., Sugimura, Y. & Verbalis, J. F. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J. Biol. Chem. 286, 10864-10875 (2011).
147. Kinsella, S., Moran, S., Sullivan, M. O., Molloy, M. G. M. & Eustace, J. A. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin. J. Am. Soc. Nephrol. 5, 275-280 (2010).
148. Hoorn, E. J. et al. Mild hyponatremia as a risk factor for fractures: the Rotterdam Study. J. Bone Miner. Res. 26, 1822-1828 (2011).
149. Ziere, G. et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J. Clin. Psychopharmacol. 28, 411-417 (2008).
150. Barsony, J., Manigrasso, M. B., Xu, Q., Tam, H. & Verbalis, J. G. Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats. Age (Dordr). http://dx.doi.org/10.1007/s11357-011-9347-9.
151. Hoorn, E. J., Liamis, G., Zietse, R. & Zillikens, M. C. Hyponatremia and bone: an emerging relationship. Nat. Rev. Endocrinol. 8, 33-39 (2011).
152. Verbalis, J. G., Goldsmith, S. R., Greenberg, A., Schrier, R. W. & Sterns, R. H. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am. J. Med. 120 (11 Suppl. 1), S1-S21 (2007).
153. Moritz, M. L. & Ayus, J. C. 100 cc 3% sodium chloride bolus: a novel treatment for hyponatremic encephalopathy. Metab. Brain Dis. 25, 91-96 (2010).
154. Koenig, M. A. et al. Reversal of transtentorial herniation with hypertonic saline. Neurology 70, 1023-1029 (2008).
155. Ayus, J. C. & Arieff, A. I. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA 281, 2299-2304 (1999).
156. Miller, P. D., Linas, S. L. & Schrier, R. W. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 243, 2513-2515 (1980).
157. Bichet, D. G. What is the role of vaptans in routine clinical nephrology? Clin. J. Am. Soc. Nephrol. 7, 700-703 (2012).
158. Decaux, G., Andres, C., Gankam Kengne, F. & Soupart, A. Treatment of euvolemic hyponatremia in the intensive care unit by urea. Crit. Care 14, R184 (2010).
159. Soupart, A., Coffernils, M., Couturier, B., Gankam-Kengne, F. & Decaux, G. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin. J. Am. Soc. Nephrol. 7, 742-747 (2012).
160. Hantman, D., Rossier, B., Kohlman, R. & Schrier, R. W. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. Ann. Intern. Med. 78, 870-875 (1973).
161. Anderson, R. J., Chung, H. M., Kluge, R. & Schrier, R. W. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann. Intern. Med. 102, 164-168 (1985).
162. Verbalis, J. G., Zeltser, D., Smith, N., Barve, A. & Andoh, M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysisof a randomized, controlled study. Clin. Endocrinol. (Oxf.) 69, 159-168 (2008).
163. Berl, T. et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J. Am. Soc. Nephrol. 21, 705-712 (2010).
164. Gullans, S. R. & Verbalis, J. G. Control of brain volume during hyperosmolar and hypoosmolar conditions. Annu. Rev. Med. 44, 289-301 (1993).
165. Sterns, R. H., Cappuccio, J. D., Silver, S. M. & Cohen, E. P. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J. Am. Soc. Nephrol. 4, 1522-1530 (1994).
166. Cluitmans, F. H. & Meinders, A. E. Management of severe hyponatremia: rapid or slow correction? Am. J. Med. 88, 161-166 (1990).
167. Ayus, J. C., Krothapalli, R. K. & Arieff, A. I. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N. Engl. J. Med. 317, 1190-1195 (1987).
168. Soupart, A., Schroëder, B. & Decaux, G. Treatment of hyponatraemia by urea decreases risks of brain complications in rats. Brain osmolyte contents analysis. Nephrol. Dial. Transplant. 22, 1856-1863 (2007).
169. Soupart, A., Silver, S., Schroöeder, B., Sterns, R. & Decaux, G. Rapid (24-hour) reaccumulation of brain organic osmolytes (particularly myo-inositol) in azotemic rats after correction of chronic hyponatremia. J. Am. Soc. Nephrol. 13, 1433-1441 (2002).
170. Ayus, J. C., Armstrong, D. & Arieff, A. I. Hyponatremia with hypoxia: effects on brain adaptation, perfusion, and histology in rodents. Kidney Int. 69, 1319-1325 (2006).
171. Schaffer, S., Solodushko, V., Pastukh, V., Ricci, C. & Azuma, J. Possible cause of taurine-deficient cardiomyopathy: potentiation of angiotensin II action. J. Cardiovasc. Pharmacol. 41, 751-759 (2003).
172. Desai, K. V. et al. Mechanics of the left ventricular myocardial interstitium: effects of acute and chronic myocardial edema. Am. J. Physiol. Heart Circ. Physiol. 294, H2428-H2434 (2008).
173. Dongaonkar, R. M., Stewart, R. H., Geissler, H. J. & Laine, G. A. Myocardial microvascular permeability, interstitial oedema, and compromised cardiac function. Cardiovasc. Res. 87, 331-339 (2010).
174. Okada, K., Ishikawa, S., Caramelo, C., Tsai, P. & Schrier, R. W. Enhancement of vascular action of arginine vasopressin by diminished extracellular sodium concentration. Kidney Int. 44, 755-763 (1993).
175. Otsuka Pharmaceutical Ltd. Direct Healthcare Professional Communication on the risk of increases in serum sodium with tolvaptan which are too rapid [online], http://www.mhra.gov.uk/home/groups/comms-ic/documents/ websiteresources/con146921.pdf (2012).
176. Gross, P. A., Wagner, A. & Decaux, G. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet. Kidney Int. 80, 594-600 (2011).